VEDANTA BIOSCIENCES INC.

Company Snapshot

Founded: 2010
Entity Type: Private
Region: U.S.
Headquarter: Massachusetts, U.S.
Key Geographics: U.S.
Corporate Address: 19 Blackstone Street Cambridge, Massachusetts 02139 U.S. Tel: +1-857-706-1427 www.vedantabio.com

Company Overview

Vedanta Biosciences Inc. develops LBPs based on bacterial consortium for GI diseases. The company constructed a proprietary strain library from healthy, well-validated subjects to introduce pharmacologically relevant properties, like the ability to induce distinct immune responses. It has a facility to manage banking, fermentation, separation, lyophilization, and formulation of bacterial drug products. Vedanta Biosciences has collaborations and partnership agreements with clinical and academic institutions to advance the understanding of the microbiome and develop microbiome drugs. It collaborated with Bristol Myers Squibb for the clinical candidate VE800 for application in immuno-oncology.

VEDANTA BIOSCIENCES INC. In Reports

Human Microbiome-based Drugs and Diagnostics: Global Markets

Our detailed report on the Human Microbiome-based Drugs and Diagnostics market includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Microbiome Therapeutics: Global Markets

Global market for microbiome therapeutics is estimated to increase from $164.8 million in 2022 to reach $1.5 billion by 2027, at a CAGR of 54.8% from 2022 through 2027.

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

Company's Business Segments

  • Products : VE202, VE303, VE707, Others
  • Services : Research and Development, Tests, Partnerships, Others

Applications/End User Industries

  • Pharmaceuticals
  • Healthcare
  • Biotechnology
  • Research Organizations
  • Life Sciences
AI Sentiment